Which has the lower trailing P/E, BMRN or COO?

COO has the lower trailing P/E: BMRN trades at 144.15 and COO at 19.26. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, BMRN or COO?

Over the past five years, BMRN grew revenue faster — BMRN at a 12.19% CAGR versus COO at 8.29%.

Is BMRN or COO more profitable?

COO runs the higher net margin — BMRN at 2.14% versus COO at 13.46%.

How have BMRN and COO total returns compared?

Over the past 10 years, BMRN delivered -4.98% and COO delivered 2.53% annualized total return. Past performance doesn't predict future results.

BioMarin Pharmaceutical Inc. (BMRN) vs The Cooper Companies, Inc. (COO)

A side-by-side comparison of BioMarin Pharmaceutical Inc. and The Cooper Companies, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BMRN

BioMarin Pharmaceutical Inc.

$10.87B

$56.22HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

COO

The Cooper Companies, Inc.

$11.01B

$56.43HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — BMRN vs COO

growth of $100 · dividends reinvested · last 10y

BMRN -39.5% (-4.9%/yr)COO +26.6% (+2.4%/yr)COO compounded faster over this window

BMRN COO

BMRN vs COO: by the numbers

•COO is the larger company ($11.01B vs $10.87B market cap).
•COO trades at the lower trailing earnings multiple (19.26 vs 144.15 P/E), one valuation lens rather than an overall verdict.
•COO converts more revenue to profit (13.46% vs 2.14% net margin).
•BMRN grew revenue faster over the past five years (12.19% vs 8.29% CAGR).

Metrics side by side

Valuation

Metric	BMRN	COO
P/E ratio	144.15	19.26
Forward P/E	N/A	12.42
P/S ratio	3.19	2.60
P/B ratio	1.72	1.32
EV / EBITDA	33.30	14.43
FCF yield	6.74%	6.16%

Profitability

Metric	BMRN	COO
Gross margin	75.55%	63.64%
Operating margin	16.56%	12.85%
Net margin	2.14%	13.46%
ROE	1.15%	6.85%
ROIC	1.40%	4.76%

Growth (annualized)

Metric	BMRN	COO
Revenue CAGR (5Y)	12.19%	8.29%
EPS CAGR (5Y)	-17.46%	-17.30%
FCF CAGR (5Y)	33.84%	5.21%
Total return CAGR (5Y)	-5.59%	-11.35%

Frequently asked

Which has the lower trailing P/E, BMRN or COO?: COO has the lower trailing P/E: BMRN trades at 144.15 and COO at 19.26. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, BMRN or COO?: Over the past five years, BMRN grew revenue faster — BMRN at a 12.19% CAGR versus COO at 8.29%.
Is BMRN or COO more profitable?: COO runs the higher net margin — BMRN at 2.14% versus COO at 13.46%.
How have BMRN and COO total returns compared?: Over the past 10 years, BMRN delivered -4.98% and COO delivered 2.53% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BMRN analysis Full COO analysis Interactive comparison tool

Dig into the metrics

BioMarin Pharmaceutical P/E ratio Cooper Companies P/E ratio BioMarin Pharmaceutical ROE Cooper Companies ROE BioMarin Pharmaceutical operating margin Cooper Companies operating margin BioMarin Pharmaceutical revenue growth Cooper Companies revenue growth BioMarin Pharmaceutical free cash flow Cooper Companies free cash flow

BioMarin Pharmaceutical & Cooper Companies appear in these rankings

Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.